减肥药物芬氟拉明在世界上已有6000万人服用过,1000万人服用过右芬氟拉明,但两种威胁生命的不良反应,原发性肺动脉高压及心瓣膜异常与芬氟拉明和右芬氟拉明因果相关。美国食品与药品管理局(FDA)下令禁用芬氟拉明和右芬氟拉明并撤出美国市场,引起许多国家对减肥药物安全性的广泛关注,如墨西哥、加拿大、哥伦比亚、法国等也立即从市场撤出此类减肥药。美国对上市后药品的 Fenfluramine, the weight-loss drug, has been taken in the world by 60 million people and 10 million people have taken dexfenfluramine, but two life-threatening adverse reactions, primary pulmonary hypertension and valvular heart abnormalities are associated with fenfluramine Ming and dexfenfluramine causative. The FDA ordered the banning of fenfluramine and dexfenfluramine and withdrawal from the U.S. market, causing widespread concern in many countries about the safety of diet pills such as Mexico, Canada, Colombia, France, etc. Market withdrawal of such diet pills. The United States on the listing of drugs